Understanding seizure causes and their warning signs together with when to seek medical help is crucial because not all ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

Bayer Aktiengesellschaft (ETR:BAYN) highlighted results from its OCEANIC-STROKE phase III trial during an investor webinar held at ISC 2026 in New Orleans, outlining what company executives and ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

TIGERTRIEVER (TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

More than 8 million people in the U.S. take blood thinners, also called anticoagulants. Many are prescribed the drugs after ...

Caveat in Chinese trial was the increased symptomatic intracranial hemorrhage risk ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Dementia risk rises dramatically in people with CAA, a condition where amyloid builds up in brain blood vessels, even when no stroke occurs.